Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Pembrolizumab as adjuvant therapy for TNBC

Abirami Sivapiragasam • 12 Sep 2022
ESMO 2022
Breast Cancer Antibodies Pembrolizumab
KEYNOTE-522

Abirami Sivapiragasam, MD, Upstate Medical University, Syracuse, NY, discusses an investigation into pembrolizumab in as adjuvant therapy for triple-negative breast cancer (TNBC). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Abirami Sivapiragasam

1:38
CompassHER2-pCR: de-escalation of neoadjuvant chemotherapy for breast cancer
Abirami Sivapiragasam • 5 Sep 2022
1:23
Molecular targets in salivary gland cancers: a comprehensive genomic analysis of 1,666 cases
Abirami Sivapiragasam • 9 Sep 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals